Related Experiment Videos
Topical sulfacetamide vs oral erythromycin for neonatal chlamydial conjunctivitis
Insights
Systemic erythromycin estolate effectively treats Chlamydia trachomatis neonatal conjunctivitis, eradicating infection. Topical sulfacetamide therapy is less effective, leading to persistent Chlamydia trachomatis infections.
Area of Science:
- Ophthalmology
- Neonatal Medicine
- Infectious Diseases
Background:
- Neonatal conjunctivitis is a common condition in newborns.
- Chlamydia trachomatis is a frequent cause of bacterial conjunctivitis in infants.
- Identifying effective treatments for Chlamydia trachomatis neonatal conjunctivitis is crucial.
Purpose of the Study:
- To compare the efficacy of oral erythromycin estolate versus topical sulfacetamide sodium for treating Chlamydia trachomatis neonatal conjunctivitis.
- To determine the eradication rates of Chlamydia trachomatis from conjunctival and nasopharyngeal sites.
Main Methods:
- Infants with purulent conjunctivitis underwent conjunctival and nasopharyngeal cultures for Chlamydia trachomatis.
- Participants were randomly assigned to receive either oral erythromycin estolate or topical sulfacetamide sodium.
- Treatment efficacy was assessed by clinical resolution and negative follow-up cultures.
Main Results:
- Chlamydia trachomatis was identified in 73% of infants with conjunctivitis.
- Oral erythromycin estolate eradicated Chlamydia trachomatis in 93% of treated infants.
- Topical sulfacetamide resulted in persistent conjunctival infection in 57% and nasopharyngeal colonization in 21%.
Conclusions:
- Chlamydia trachomatis is the predominant cause of neonatal conjunctivitis in the studied urban population.
- Oral erythromycin estolate is a highly effective treatment for eradicating Chlamydia trachomatis neonatal conjunctivitis and colonization.
- Topical sulfacetamide therapy is associated with treatment failure and persistent infection.
Abstract:
Conjunctival and nasopharyngeal cultures for Chlamydia trachomatis were obtained from infants 30 days of age or younger with purulent conjunctivitis. Conjunctival specimens were also tested for other bacterial pathogens and for viruses. Most of the infants studied were black and came from a low-income, urban population. By random assignment infants received either topical treatment with 10% sulfacetamide sodium ophthalmic solution or systemic treatment with oral erythromycin estolate (50 mg/kg/day). Treatment was continued for 14 days if C trachomatis was isolated from the conjunctivae. Treatment was considered to be effective if conjunctivitis resolved and if follow-up chlamydial cultures of the conjunctivae and nasopharynx were negative at completion of therapy and two to four weeks later. Chlamydia trachomatis was isolated in the absence of other pathogens from the eyes of 37 (73%) of 51 infants with conjunctivitis. Other bacterial pathogens were isolated from four infants (8%) and viruses from none. Chlamydial infection was eradicated from 14 (93%) of 15 infants treated orally. In contrast, persistent conjunctival infection was detected in eight infants (57%) and nasopharyngeal colonization in three (21%) of 14 infants after topical treatment. It was concluded that C trachomatis is the most frequent cause of neonatal conjunctivitis in the low-income, urban population studied; that erythromycin estolate administered orally for 14 days eradicates chlamydial conjunctival and nasopharyngeal infection; and that topical sulfacetamide therapy may result in persistent conjunctival infection and nasopharyngeal colonization.